Dr. Gavin Samuels, Chief Business Officer at CinRx, a holding company currently with six portfolio companies, each focused on developing one drug. Providing these companies with the right resources at the right time makes for more efficient use of resources and can speed up drug development. Their strength is understanding challenges and opportunities approximately a year before an IND is filed to help shepherd the drug through the IND-enabling study and through clinical development.

Gavin elaborates, "The disease areas that we're involved in, cardiovascular disease, metabolic disease, inflammatory diseases, these are problems that present a real challenge to patients and a real challenge to society and a real challenge to humanity. We want to try and address those problems by bringing innovative drugs and developing them as quickly and efficiently as possible and bringing to the patient."

"The criteria we use is that it has to fit a specific unmet medical need. We have to have a large group of patients that are involved in the disease, that have the disease, and we want to make sure that we can make a meaningful difference to the way that the disease is treated as well as the quality of life for the patient. So we don't want incremental improvements. We're looking for drugs that are going to make step changes in the quality of life of the patients we are trying to bring the medicine to."

#CinRx #CinRxSuperHighway #TransformationalMedicines #DrugDevelopment #Obesity #TypeOneDiabetes #T1D #Hypertension #Gastroparesis #IrritableBowelSyndrome #SolidTumors #Oncology #NeurodegenerativeDiseases

cinrx.com

Listen to the podcast here